These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29754812)

  • 21. HF Etiology and cardiac contractility modulation therapy.
    Davtyan K; Chugunov I; Topchyan A; Mareev Y; Mironova N; Rimskaya E; Golitsyn S; Mikhaylov E; Lebedev D; Vander M; Lyasnikova E; Sitnikova M; Minjia K; Glembo S; Sukhorukov O
    BMC Cardiovasc Disord; 2024 May; 24(1):279. PubMed ID: 38811946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Mando R; Goel A; Habash F; Saad M; Ayoub K; Vallurupalli S; Maskoun W
    Cardiovasc Ther; 2019; 2019():9769724. PubMed ID: 31772622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
    Anker SD; Coats AJ; Cristian G; Dragomir D; Pusineri E; Piredda M; Bettari L; Dowling R; Volterrani M; Kirwan BA; Filippatos G; Mas JL; Danchin N; Solomon SD; Lee RJ; Ahmann F; Hinson A; Sabbah HN; Mann DL
    Eur Heart J; 2015 Sep; 36(34):2297-309. PubMed ID: 26082085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
    Abraham WT; Zile MR; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    JACC Heart Fail; 2015 Jun; 3(6):487-496. PubMed ID: 25982108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
    Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does contractility modulation have a role in the treatment of heart failure?
    Burkhoff D
    Curr Heart Fail Rep; 2011 Dec; 8(4):260-5. PubMed ID: 21656201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure.
    Abraham WT; Aggarwal S; Prabhu SD; Cecere R; Pamboukian SV; Bank AJ; Sun B; Pae WE; Hayward CS; McCarthy PM; Peters WS; Verta P; Slaughter MS;
    JACC Heart Fail; 2014 Oct; 2(5):526-33. PubMed ID: 25301151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond.
    Tschöpe C; Kherad B; Klein O; Lipp A; Blaschke F; Gutterman D; Burkhoff D; Hamdani N; Spillmann F; Van Linthout S
    Eur J Heart Fail; 2019 Jan; 21(1):14-22. PubMed ID: 30485591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure.
    Stix G; Borggrefe M; Wolpert C; Hindricks G; Kottkamp H; Böcker D; Wichter T; Mika Y; Ben-Haim S; Burkhoff D; Wolzt M; Schmidinger H
    Eur Heart J; 2004 Apr; 25(8):650-5. PubMed ID: 15084369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
    De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR
    J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tai chi exercise in patients with chronic heart failure: a randomized clinical trial.
    Yeh GY; McCarthy EP; Wayne PM; Stevenson LW; Wood MJ; Forman D; Davis RB; Phillips RS
    Arch Intern Med; 2011 Apr; 171(8):750-7. PubMed ID: 21518942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac contractility modulation in patients with heart failure - A review of the literature.
    Bazoukis G; Saplaouras A; Efthymiou P; Yiannikourides A; Liu T; Letsas KP; Efremidis M; Lampropoulos K; Xydonas S; Tse G; Armoundas AA
    Heart Fail Rev; 2024 May; 29(3):689-705. PubMed ID: 38393423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration.
    Kloppe A; Lawo T; Mijic D; Schiedat F; Muegge A; Lemke B
    Int J Cardiol; 2016 Apr; 209():291-5. PubMed ID: 26908357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizer Smart in the treatment of moderate-to-severe chronic heart failure.
    Campbell CM; Kahwash R; Abraham WT
    Future Cardiol; 2020 Jan; 16(1):13-25. PubMed ID: 31825245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proportion of Patients Eligible for Cardiac Contractility Modulation: Real-Life Data from a Single-Center Heart Failure Clinic.
    Pilecky D; Muk B; Majoros Z; Vágány D; Kósa K; Szabó M; Szögi E; Dékány M; Kiss RG; Nyolczas N
    Cardiology; 2021; 146(2):195-200. PubMed ID: 33582674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial.
    Feldman T; Mauri L; Kahwash R; Litwin S; Ricciardi MJ; van der Harst P; Penicka M; Fail PS; Kaye DM; Petrie MC; Basuray A; Hummel SL; Forde-McLean R; Nielsen CD; Lilly S; Massaro JM; Burkhoff D; Shah SJ;
    Circulation; 2018 Jan; 137(4):364-375. PubMed ID: 29142012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation.
    Röger S; Schneider R; Rudic B; Liebe V; Stach K; Schimpf R; Borggrefe M; Kuschyk J
    Europace; 2014 Aug; 16(8):1205-9. PubMed ID: 24706089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study.
    Liu M; Fang F; Luo XX; Shlomo BH; Burkhoff D; Chan JY; Chan CP; Cheung L; Rousso B; Gutterman D; Yu CM
    Int J Cardiol; 2016 Mar; 206():122-6. PubMed ID: 26788686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.
    Young JB; Abraham WT; Smith AL; Leon AR; Lieberman R; Wilkoff B; Canby RC; Schroeder JS; Liem LB; Hall S; Wheelan K;
    JAMA; 2003 May; 289(20):2685-94. PubMed ID: 12771115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.
    Ambrosy AP; Bhatt AS; Stebbins AL; Wruck LM; Fudim M; Greene SJ; Kraus WE; O'Connor CM; Piña IL; Whellan DJ; Mentz RJ
    Am Heart J; 2018 May; 199():97-104. PubMed ID: 29754673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.